Camacho A E, Cobo R, Otte J, Spector S L, Lerner C J, Garrison N A, Miniti A, Mydlow P K, Giguere G C, Collins J J
Universidad del Valle, Cali, Colombia.
Am J Med. 1992 Sep;93(3):271-6. doi: 10.1016/0002-9343(92)90232-z.
This multicenter study compared the clinical and bacteriologic efficacy of two oral antibiotics, cefuroxime axetil and amoxicillin/clavulanate, in the treatment of acute bacterial maxillary sinusitis.
Three hundred seventeen patients with clinical and radiographic evidence of acute maxillary sinusitis were enrolled at nine centers and were randomly assigned to receive 10 days of treatment with cefuroxime axetil 250 mg twice daily (n = 157) or amoxicillin/clavulanate 500 mg three times daily (n = 160). Patients were assessed for both clinical and bacteriologic responses once during treatment (5 to 7 days) and twice after treatment (1 to 3 days and 4 weeks). Bacteriologic assessments were based on needle aspirates of the maxillary sinus obtained pretreatment and, when possible, at the first posttreatment visit.
Organisms were isolated from the pretreatment sinus aspirates of 198 of 317 (62%) patients, with the primary isolates being Streptococcus pneumoniae (22%), Haemophilus spp. (17%), Staphylococcus aureus (13%), and Haemophilus influenzae (10%). A satisfactory clinical outcome (cure or improvement) was achieved in 85% (98 of 115) and 82% (102 of 124) of the clinically evaluable patients treated with cefuroxime axetil or amoxicillin/clavulanate, respectively (P = 0.446). With respect to the eradication of the bacterial pathogens, a satisfactory outcome (cure or presumed cure) was obtained in 84% (31 of 37) and 87% (34 of 39) of bacteriologically evaluable patients treated with cefuroxime axetil or amoxicillin/clavulanate, respectively (p = 0.567). Treatment with amoxicillin/clavulanate was associated with a significantly higher incidence of drug-related adverse events (13% versus 3%, p = 0.001), particularly diarrhea (8% versus 1%, p = 0.001). Two patients in the cefuroxime axetil group and three patients in the amoxicillin/clavulanate group withdrew from the study due to adverse events.
Our results indicate that cefuroxime axetil twice a day is as effective as amoxicillin/clavulanate three times a day in the treatment of acute bacterial maxillary sinusitis but produces fewer adverse effects.
本多中心研究比较了两种口服抗生素头孢呋辛酯和阿莫西林/克拉维酸在治疗急性细菌性上颌窦炎方面的临床和细菌学疗效。
9个中心招募了317例有急性上颌窦炎临床和影像学证据的患者,随机分配接受为期10天的治疗,其中157例患者每日两次口服250mg头孢呋辛酯,160例患者每日三次口服500mg阿莫西林/克拉维酸。在治疗期间(5至7天)对患者进行一次临床和细菌学反应评估,治疗后(1至3天和4周)进行两次评估。细菌学评估基于治疗前获取的上颌窦穿刺抽吸物,并且在可能的情况下,在治疗后的首次就诊时进行。
在317例患者中的198例(62%)的治疗前鼻窦抽吸物中分离出微生物,主要分离菌为肺炎链球菌(22%)、嗜血杆菌属(17%)、金黄色葡萄球菌(13%)和流感嗜血杆菌(10%)。接受头孢呋辛酯或阿莫西林/克拉维酸治疗的可临床评估患者中,分别有85%(115例中的98例)和82%(124例中的102例)取得了满意的临床结果(治愈或改善)(P = 0.446)。在细菌病原体根除方面,接受头孢呋辛酯或阿莫西林/克拉维酸治疗的可细菌学评估患者中,分别有84%(37例中的31例)和87%(39例中的34例)取得了满意的结果(治愈或推定治愈)(p = 0.567)。阿莫西林/克拉维酸治疗相关的药物不良事件发生率显著更高(13%对3%,p = 0.001),尤其是腹泻(8%对1%,p = 0.001)。头孢呋辛酯组有2例患者和阿莫西林/克拉维酸组有3例患者因不良事件退出研究。
我们的结果表明,每日两次服用头孢呋辛酯在治疗急性细菌性上颌窦炎方面与每日三次服用阿莫西林/克拉维酸效果相同,但不良反应更少。